Abstracts tagged "Autoantibody(ies)"

Abstract Number: 2447 • ACR Convergence 2024
Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort
Roberto D'Alessandro¹, Stefano Rodolfi², Alix Calot¹, Louis Bébéar³, Corrado Campochiaro⁴, Veronica Codullo⁵, Francesco Del Galdo⁶, Ivan Castellvi Barranco⁷, Elisabetta Zanatta⁸, Silvia Bellando Randone⁹, Goncalo Boleto¹⁰, Loic Raffray¹¹, Emmanuel Chatelus¹², Patrice Cacoub¹³, Alexandre Le Joncour¹³, Paolo Airò¹⁴, cristiana sieiro santos¹⁵, Alain Lescoat¹⁶, Jérôme Avouac¹⁷, Christopher Denton¹⁸ and Yannick Allanore¹⁹, ¹Rheumatology Department, Cochin Hospital, Université Paris Cité, APHP, Paris, France, Paris, France, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, UK, London, United Kingdom, ³Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France., Bordeaux, France, ⁴IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ⁵Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ⁶University of Leeds, Leeds, United Kingdom, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Unit of Rheumatology, Padova University, Padova, Italy, ⁹Department of Experimental and Clinical Medicine University of Florence Division of Rheumatology Scleroderma Unit, Careggi Hospital Florence, Italy, Florence, Toscana, Italy, ¹⁰Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, ¹¹CHU La Réunion - Competence center for autoimmune diseases, Internal Medicine, Saint-Denis, Reunion, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, 75013 Paris, France, Paris, France, ¹⁴Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ¹⁵Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ¹⁶Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France, rennes, France, ¹⁷Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ¹⁸University College London, Northwood, United Kingdom, ¹⁹Rheumatology department, Université Paris Cité, Cochin Hospital of Paris; France, Paris, France
Background/Purpose: Anti-fibrillarin (AFA) auto-antibodies are rarely found in Systemic Sclerosis (SSc). Beyond the ethnic association with a higher prevalence in patients of Black ethnicity, the…
Abstract Number: 0098 • ACR Convergence 2024
Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Jorge Armando Gonzalez-Chapa¹, Anders Bengtsson², Iva Gunnarsson³, Elisabet Svenungsson⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Lund University, Lund, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
Abstract Number: 0444 • ACR Convergence 2024
Deep Serologic Profiling Identifies Novel Autoantibodies Associated with Fetal Atrioventricular Block
Philip Carlucci¹, Robert Clancy², Mala Masson³, Colin Phoon⁴, Ashley Roman⁴, Peter Izmirly⁵, Amit Saxena⁶, H Michael Belmont⁴, Christina Penfield⁴, Young Mi Lee⁴, Julie Nusbaum⁷, Andrew Rubenstein⁴, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Abuhamad⁹, Karla Bermudez-Wagner⁹, Majd Makhoul¹⁰, Gary Satou¹¹, Whitnee Hogan¹², Nelangi Pinto¹³, Anita Moon-Grady¹⁴, Lisa Howley¹⁵, Mary Donofrio¹⁶, Anita Krishnan¹⁶, Jaclyn Phillips¹⁷, Stephanie Levasseur¹⁸, Miwa Geiger¹⁹, Erin Paul²⁰, Sonal Owens²¹, Kristopher Cumbermack²², Jyothi Matta²³, Gary Joffe²⁴, Christopher Lindblade²⁵, Carl Weiner²⁶, Caitlin Haxel²⁷, Katherine Kohari²⁸, Joshua Copel²⁸, James Strainic²⁹, Tam Doan³⁰, Shreya Sheth³⁰, Stacy Killen³¹, Theresa Tacy³², Michelle Kaplinski³², Nicola Fraser⁴, Kelly Ruggles³³, Bettina Cuneo³⁴ and Jill Buyon³⁵, ¹New York University School of Medicine, New York, NY, ²Columbia University Medical Center, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴NYU Langone Health, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷NYU Langone Hospital - Long Island, Internal Medicine - Rheumatology, Mineola, NY, ⁸Children's Heart Center, Las Vegas, NV, ⁹Eastern Virginia Medical School, Norfolk, VA, ¹⁰Atrium Health Levine Children's Hospital, Charlotte, NC, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Utah, Salt Lake City, UT, ¹³Seattle Children's Hospital, Seattle, WA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁶Children's National Hospital, Washington, DC, ¹⁷George Washington University, Washington, DC, ¹⁸Columbia University, New York, NY, ¹⁹Mount Sinai School of Medicine, New York, NY, ²⁰Atlantic Health System, Morristown, NJ, ²¹University of Michigan, Ann Arbor, MI, ²²University of Kentucky, Lexington, KY, ²³University of Louisville, Louisville, KY, ²⁴Perinatal Associates of New Mexico, Albuquerque, NM, ²⁵Phoenix Children's Hospital, Phoenix, AZ, ²⁶Dignity Health, Phoenix, AZ, ²⁷University of Vermont Children's Hospital, Burlington, VT, ²⁸Yale University, New Haven, CT, ²⁹UH Rainbow Babies, Cleveland, OH, ³⁰Baylor College of Medicine, Houston, TX, ³¹Vanderbilt University, Nashville, TN, ³²Stanford University, Stanford, CA, ³³NYU Grossman School of Medicine, Brooklyn, NY, ³⁴University of Arizona College of Medicine, Tucson, AZ, ³⁵New York University Grossman School of Medicine, New York, NY
Background/Purpose: Maternal anti-SSA/Ro52/60kD autoantibodies are necessary for the development of fetal atrioventricular block (AVB) but titers alone are not sufficient to predict the likelihood of…
Abstract Number: 0840 • ACR Convergence 2024
The Platelet Adenosinergic Axis as a Novel Therapeutic Target for Thrombotic APS
NaveenKumar Somanathapura K¹, Thalia Newman², Srilakshmi Yalavarthi¹, Bruna Mazetto Fonseca¹, Kaitlyn Sabb¹, Katarina Kmetova³, Emily Chong¹, Caroline Ranger¹, Cyrus Sarosh⁴, Jacqueline Madison¹, Ajay Tambralli¹, Jordan Schaefer¹, Michael Holinstat¹, Yu Zuo¹ and Jason Knight¹, ¹University of Michigan, Ann arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: How to most effectively inhibit antiphospholipid antibodies (aPL)-mediated platelet activation remains incompletely understood. CD73 is an ectoenzyme expressed on the platelet surface that generates…
Abstract Number: 1490 • ACR Convergence 2024
Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Vasileios Kyttaris¹, Andrew Concoff², Touba Warsi³, Sepehr Taghavi³, Sudha Kumar³, Stanley Park³, Abigail Patalinghug³, Christine Schleif³, Brittany Partain⁴, Joseph Ahearn⁵, Nicole Wilson⁶, Chau-Ching Liu⁶, Susan Manzi⁶ and Tyler O'Malley⁷, ¹BIDMC, Boston, MA, ²Exagen, Inc., Los Angeles, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Allegheny Health Network, Wexford, PA, ⁶Allegheny Health Network, Pittsburgh, PA, ⁷Exagen, Vista, CA
Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
Abstract Number: 1687 • ACR Convergence 2024
IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases
Ioannis Parodis¹, Dionysis Nikolopoulos², Julius Lindblom³, Denis Lagutkin³, Lorenzo Beretta⁴, Maria Orietta Borghi⁵, Janique Peyper⁶, Guillermo Barturen⁷, Per-Johan Jakobsson³, Marta Alarcon-Riquelme⁸, Natalia Sherina³ and Helena Idborg⁹, and PRECISESADS Clinical Consortium, ¹Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ⁵Università degli Studi di Milano Statale, Milano, Italy, ⁶Sengenics Corporation Pte Ltd, Singapore, Singapore, ⁷Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁸Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁹Karolinska Institutet, Solna, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by the production of a multitude of autoantibodies (abs). The diagnosis of SLE is supported by the presence…
Abstract Number: 2065 • ACR Convergence 2024
Proposed Pathways Involved in the Pathogenesis of Juvenile Dermatomyositis (JDM)
Samantha Coss¹, Danlei Zhou¹, Rabheh Abdul Aziz², Katherine Miller³, Shoghik Akoghlanian⁴, Kyla Driest¹, Edward Oberle¹, Vidya Sivaraman⁵, Charles Spencer⁶, Stacy Ardoin¹ and Chack-Yung Yu⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²University at Buffalo, Buffalo, NY, ³Nationwide Children's Hospital, Institute for Genomic Medicine, Columbus, OH, ⁴Nationwide Children�s Hospital, Columbus, OH, ⁵Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁶University of Mississippi Medical Center, Jackson, MS, ⁷Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, OH
Background/Purpose: JDM is an autoimmune disease of skin and muscle. We investigated genetic factors, autoantibodies, and clinical features in JDM.Methods: Subjects came from 2 large…
Abstract Number: 2471 • ACR Convergence 2024
Association of Telangiectasias with Autoantibodies and Clinical Manifestations in Systemic Sclerosis
Namitha Nair¹, Thomas Medsger, Jr², Robert Lafyatis³, Maureen Laffoon⁴, Leigh Freno⁴ and Robyn Domsic⁵, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴UPMC, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Telangiectasias (Tel) are visibly dilated cutaneous post-capillary venules reported to occur in about 75% of patients with systemic sclerosis (SSc), making them a common…
Abstract Number: 0105 • ACR Convergence 2024
Novel Autoantibodies Identified in the Antiphospholipid Syndrome
Shikai Hu¹, Yangzhong Zhou¹, Menghua Cai¹, Mengtao Li² and JIULIANG ZHAO¹, ¹Peking Union Medical College Hospital, Beijing, China, ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China
Background/Purpose: The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous, or microvascular thrombosis, recurrent pregnancy morbidity, or non-thrombotic manifestations in the…
Abstract Number: 0458 • ACR Convergence 2024
Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Sara Achenbach³ and Elena Myasoedova², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
Abstract Number: 0868 • ACR Convergence 2024
Autoantibodies to Joint-related Proteins Predict Severe Joint Destruction in Difficult-to-treat Rheumatoid Arthritis Patients
Inger Gjertsson¹, Monica Leu Agelii², Outi Sareila³, Erik Lönnblom⁴, Lennart TH Jacobsson⁵, Lei Cheng⁴, Kristina Forslind⁶, Ingiäld Hafström⁷, Maria Andersson⁸ and Rikard Holmdahl⁹, ¹University of Gothenburg, Gothenburg, Sweden, ²Institutionen för medicin, avd för reumatologi och inflammationsforskning, Goteborg, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Malmö, Sweden, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, ⁷Karolinska Institutet, Department of Medicine Huddinge, Division of Gastroenterology and Rheumatology, and Karolinska University Hospital, Stockholm, Sweden, ⁸FoU Spenshult, Halmstad, Sweden, ⁹Department of Rheumatology and Inflammation Research, Institute for Medicine, Sahlgrenska Academy, University of Gothenburg, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Although treatment of rheumatoid arthritis (RA) has improved there is still a significant number of patients who never reach low disease activity, known as…
Abstract Number: 1496 • ACR Convergence 2024
Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus
Loqmane seridi¹, Steven Leonardo², Brittney Scott³, Robert Gordon¹, cathye shu¹, Kaiyin Fei¹, Kim Lo³, Anne Stevens¹ and Sheng Gao³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, ³Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA
Background/Purpose: SLE is a heterogeneous autoimmune disease affecting multiple organ systems, making clinical trial design challenging. Biomarkers that can identify patients with specific clinical manifestations…
Abstract Number: 1701 • ACR Convergence 2024
STING Pathway Activity in SLE Patient Serum Correlates with NFkB Activation, Autoantibody Levels, and a Unique Cytokine Profile That Drives Disease Activity
Hyun Hee Kim¹, Haochen Jiang², Tatiana Ort³, Gary Sims³ and Richard Hanna⁴, ¹AstraZeneca, Gaithersburg, MD, ²University of Nebraska, Omaha, NE, ³Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁴AstraZeneca, Dickerson, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous systemic autoimmune disease which is associated with innate immune activation, type I IFN, inflammasome and NFkB-related cytokines.…
Abstract Number: 2072 • ACR Convergence 2024
Clinical and Laboratory Features Associated with Pulmonary Involvement in Patients with Inflamatory Myopathy
Sonja Praprotnik¹, Katja Perdan-Pikmajer², Katja Lakota³, Ziga Rotar⁴ and Alojzija Hocevar⁵, ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ³UMC Ljubljana, Ljubljana, Slovenia, ⁴University Clinical Center, Ljubljana, Slovenia, ⁵University Medical Center Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: Polymyositis (PM), dermatomyositis (DM), and anti-synthetase syndrome (AS) are conditions included among idiopathic inflammatory myopathies (IMs).. Interstitial lung disease (ILD) is one of the…
Abstract Number: 2472 • ACR Convergence 2024
Are Anti-centromere Antibodies (aCENP) Predictive of Systemic Sclerosis Development in Patients Without Raynaud´s Phenomenon?
Andrea Alvear-Torres¹, María José Martínez-Becerra², María Carmen Vegas-Sánchez³, Sheila Recuero-Díaz¹, María Pérez-ferro⁴ and Olga Sánchez-Pernaute⁵, ¹Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ²Department of Immunology. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ³Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ⁴Department of Rheumatology. Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁵Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain
Background/Purpose: Anti-centromere (aCENP) antibodies are considered highly specific of systemic sclerosis (SSc), typically defining a limited cutaneous phenotype, usually associated to Raynaud´s phenomenon (RP). It…

« Previous Page
1
…
8
9
10
11
12
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].